Twist Bioscience (NASDAQ:TWST) Given Buy Rating at Guggenheim

Guggenheim reissued their buy rating on shares of Twist Bioscience (NASDAQ:TWST) in a research note published on Tuesday,Benzinga reports. Guggenheim currently has a $50.00 target price on the stock.

A number of other brokerages also recently commented on TWST. Robert W. Baird lowered their price target on shares of Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating for the company in a report on Tuesday. Barclays dropped their price target on Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating for the company in a research note on Thursday, April 10th. Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Finally, JPMorgan Chase & Co. cut their price target on shares of Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating on the stock in a report on Tuesday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $50.40.

Twist Bioscience Stock Performance

NASDAQ:TWST opened at $32.67 on Tuesday. The stock has a market cap of $1.96 billion, a PE ratio of -9.66 and a beta of 2.54. Twist Bioscience has a fifty-two week low of $31.56 and a fifty-two week high of $60.90. The firm’s fifty day simple moving average is $38.81 and its 200-day simple moving average is $43.74. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business had revenue of $92.79 million during the quarter, compared to analyst estimates of $92.00 million. Analysts expect that Twist Bioscience will post -2.12 earnings per share for the current fiscal year.

Insider Activity

In other Twist Bioscience news, SVP Paula Green sold 918 shares of the company’s stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total value of $37,555.38. Following the transaction, the senior vice president now directly owns 130,912 shares of the company’s stock, valued at $5,355,609.92. This represents a 0.70 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO Patrick John Finn sold 2,058 shares of the stock in a transaction that occurred on Wednesday, April 23rd. The stock was sold at an average price of $39.99, for a total transaction of $82,299.42. Following the sale, the chief operating officer now owns 265,460 shares in the company, valued at $10,615,745.40. This represents a 0.77 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,991 shares of company stock worth $742,654. 3.01% of the stock is currently owned by corporate insiders.

Institutional Trading of Twist Bioscience

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Barclays PLC boosted its position in Twist Bioscience by 214.8% during the third quarter. Barclays PLC now owns 153,039 shares of the company’s stock valued at $6,913,000 after acquiring an additional 104,420 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in Twist Bioscience in the third quarter valued at approximately $34,000. Franklin Resources Inc. boosted its holdings in shares of Twist Bioscience by 3.4% during the 3rd quarter. Franklin Resources Inc. now owns 252,064 shares of the company’s stock worth $11,756,000 after buying an additional 8,308 shares in the last quarter. Principal Financial Group Inc. grew its position in shares of Twist Bioscience by 67.5% during the 3rd quarter. Principal Financial Group Inc. now owns 205,864 shares of the company’s stock worth $9,301,000 after buying an additional 82,953 shares during the period. Finally, Avanza Fonder AB bought a new stake in shares of Twist Bioscience in the 4th quarter valued at $1,059,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.